Guardant Health Appoints New CEO, Adds Directors

TL;DR

New CEO Amirali Talasaz takes over Guardant Health, board gets shake-up.

AI Summary

Guardant Health, Inc. announced on May 24, 2024, a change in its board of directors. Specifically, Dr. Amirali Talasaz has been appointed as the new Chief Executive Officer, succeeding Helmy Eltoukhy. The company also announced the election of two new directors, Ms. Sarah Cannon and Mr. David E. R. Gross, to its Board of Directors.

Why It Matters

This filing indicates a significant leadership transition at Guardant Health, with a new CEO and board members, which could signal a shift in strategic direction or operational focus for the company.

Risk Assessment

Risk Level: medium — Leadership changes and board restructuring can introduce uncertainty regarding future strategy and execution, impacting investor confidence.

Key Players & Entities

• Guardant Health, Inc. (company) — Registrant
• Dr. Amirali Talasaz (person) — Appointed Chief Executive Officer
• Helmy Eltoukhy (person) — Departing Chief Executive Officer
• Ms. Sarah Cannon (person) — Elected Director
• Mr. David E. R. Gross (person) — Elected Director
• May 24, 2024 (date) — Date of earliest event reported

FAQ

From the Filing

0001193125-24-151836.txt : 20240531 0001193125-24-151836.hdr.sgml : 20240531 20240531162531 ACCESSION NUMBER: 0001193125-24-151836 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240524 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240531 DATE AS OF CHANGE: 20240531 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 241010127 BUSINESS ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 8-K 1 d809302d8k.htm 8-K 8-K false 0001576280 0001576280 2024-05-24 2024-05-24     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2024     GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38683   45-4139254 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (IRS Employer Identification No.) 3100 Hanover Street Palo Alto , California 94304 (Address of principal executive offices) (Zip Code) 855 - 698-8887 (Registrant’s telephone number, include area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.00001 par value per share   GH   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Following a market-focused review that began in late 2023, on May 24, 2024, the Compensation Committee of the Board of Directors of Guardant Health, Inc. (the “Company”) approved an amendment and restatement to the Guardant Health, Inc. Executive Severance Plan (the “Executive Severance Plan” and as amended, the “Amended Severance Plan”) that applies to all executive employees. The material terms and conditions of the Amended Severance Plan as they relate to the Company’s named executive offi